A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Clicks: 584
ID: 111036
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 41 articles by views in annals of the rheumatic diseases

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CT-P13 demonstrated equivalent efficacy to INX at week 30, with a comparable PK profile and immunogenicity. CT-P13 was well tolerated, with a safety profile comparable with that of INX. CLINICALTRIALS.GOV IDENTIFIER: NCT01217086.
Reference Key
dh2013annalsa Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yoo DH;Hrycaj P;Miranda P;Ramiterre E;Piotrowski M;Shevchuk S;Kovalenko V;Prodanovic N;Abello-Banfi M;Gutierrez-Ureña S;Morales-Olazabal L;Tee M;Jimenez R;Zamani O;Lee SJ;Kim H;Park W;Müller-Ladner U;;
Journal annals of the rheumatic diseases
Year 2013
DOI
DOI not found
URL
https://www.pubmed.gov/23687260/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male adolescent aged middle aged young adult Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal / therapeutic use* Double-Blind Method Multicenter Study severity of illness index drug therapy combination pmid:23687260 pmc3786641 doi:10.1136/annrheumdis-2012-203090 dae hyun yoo pawel hrycaj ulf müller-ladner monoclonal / adverse effects monoclonal / blood antirheumatic agents / adverse effects antirheumatic agents / blood antirheumatic agents / therapeutic use* arthritis rheumatoid / blood rheumatoid / drug therapy* immunoglobulin g / adverse effects immunoglobulin g / blood immunoglobulin g / therapeutic use* infliximab methotrexate / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.